@article{lin2012concurrent,
  title = {Concurrent Chemoradiation for T3 Glottic Squamous Cell Carcinoma: A Reasonable Alternative to Upfront Laryngectomy},
  author = {Charles Lin and Edward Sia and Jacqui Keller},
  year = 2012,
  url = {https://ibimapublishing.com/articles/ACRT/2012/461217/},
  journal = {Advances in Cancer Research & Treatment},
  volume = 2012 (2012),
  pages = 8,
  doi = 10.5171/2012.461217,
  abstract = {Introduction Upfront treatment options for stage III and IV larynx Squamous Cell Carcinoma (SCC) include laryngectomy or chemoradiation (CRT). The functional consequence of laryngectomy is debilitating (instant loss of voice in most cases) and significantly affects patients’ quality of life. This study examined the rate of organ preservation and associated late morbidity for T3N+/-M0 glottic SCC treated with upfront concurrent CRT. Methods Between January 2000 and November 2007, 17 patients presented with T3N+/-M0 glottic SCC and were treated with definitive concurrent CRT at the Royal Brisbane and Women's Hospital, Australia. The primary end point was laryngectomy free survival at 5 years (5Yr LFS). The secondary end points were 5 years local control (5Yr LC), relapse free survival (5Yr RFS), disease specific survival (5Yr DSS) and overall survival (5Yr OS). Prevalence of  grade 2 voice changes and dysphagia were also reported. Results The rate of 5Yr LFS, 5Yr RFS, 5Yr LC, 5Yr DSS and 5Yr OS were 81%, 71%, 87%, 89%, and 89% respectively, The prevalence of ≥ grade 2 voice changes at 12 months post-treatment and date last seen were 44% and 33% respectively. The prevalence of ≥ grade 2 dysphagia at 12 months post-treatment and date last seen were 6% and 6% respectively.ConclusionsDefinitive concurrent CRT is a reasonable alternative to upfront laryngectomy for patients with T3N+/-M0 glottic carcinoma without significant morbidities.},
  keywords = {Organ Preservation; Concurrent Chemoradiation; Glottis; Squamous Cell Carcinoma.},
  note = Article ID: 461217
}